lenalidomide,tafasitamab
incyte,morphosys
['firstmind', 'lymsm', 'dlbcl']
firstmind trial. tafa/len plus rchop by dr. kurtz saturdar, poster session. n=19 dlbcl pts. cr84% (mrd-ve 100%) progression/dead 16% (mrd+ve 100%). salvage 2 pts. 1 died by progression 1 was salvaged with mrd-ve.detection in plasma or tumor r2=0.99.promising data #ash22 #lymsm 
Happily married. Hematologist & Stem Cell Transplanter. field of interest: lymphoma-myeloma and chemoresistance biomarkers. @HematoClinicBCN @hematosantpau. EHS